Here at Emergex Vaccines Holding Ltd, we are pioneering a new approach to vaccine development, in order to address some of the world’s most acute health threats such as Zika, Ebola, pandemic flu and antibiotic-resistant bacteria. We have developed a novel and ground-breaking approach to making vaccines, using purely synthetic components to activate T-cells of the immune system to destroy virus-infected human cells.
We use unique technologies to develop our vaccines including the construction of a library of immunogenic peptides and a gold nanoparticle delivery system. These state-of-the-art technologies, together with superior science, allows us to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.
Our business model is initially focussed on creating an International Vaccine Repository of post Phase I vaccines, for subscription by governments, non-governmental organisations and charities to act as a first line of defence against existing and newly emerging infectious outbreaks. Access to this repository is expected to provide us with our first revenues. However, we are also planning to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.
We operate a streamlined commissioning structure and will advance our pipeline of vaccines into Phase I clinical development. We will use collaborators to develop our vaccines; we therefore do not require our own laboratories or manufacturing facilities as yet.
We are a member of the Social Stock Exchange which provides access to the world’s first regulated exchange, dedicated to businesses and investors who are seeking to achieve a positive social and environmental impact through their activities.